[1]Thysen S,Luyten FP,Lories RJ.Targets,models and challenges in osteoarthritis research[J].Dis Model Mech,2015,8(1):17-30.
[2]薛庆云,王坤正,裴福兴,等.中国40岁以上人群原发性骨关节炎患病状况调查[J].中华骨科杂志,2015,35(12):1206-1212.
[3]Mobasheri A,Matta C,Zakany R,et al.Chondrosenescence:definition,hallmarks and potential role in the pathogenesis of osteoarthritis[J].Maturitas,2015,80(3):237-244.
[4]Robinson WH,Lepus CM,Wang Q,et al.Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis[J].Nat Rev Rheumatol,2016,12(10):580-592.
[5]Zhuo Q,Yang W,Chen J,et al.Metabolic syndrome meets osteoarthritis[J].Nat Rev Rheumatol,2012,8(12):729-737.
[6]Iwasaki A,Medzhitov R.Control of adaptive immunity by the innate immune system[J].Nat Immunol,2015,16(4):343-353.
[7]Scanzello CR,Plaas A,Crow MK.Innate immune system activation in osteoarthritis:is osteoarthritis a chronic wound?[J].Curr Opin Rheumatol,2008,20(5):565-572.
[8]Orlowsky EW,Kraus VB.The role of innate immunity in osteoarthritis:when our first line of defense goes on the offensive[J].J Rheumatol,2015,42(3):363-371.
[9]Kalaitzoglou E,Griffin TM,Humphrey MB.Innate immune responses and osteoarthritis[J].Curr Rheumatol Rep,2017,19(8):1-6.
[10]Carroll MV,Sim RB.Complement in health and disease[J].Adv Drug Deliv Rev,2011,63(12):965-975.
[11]Gobezie R,Kho A,Krastins B,et al.High abundance synovial fluid proteome:distinct profiles in health and osteoarthritis[J].Arthritis Res Ther,2007,9(2):1-15.
[12]Wang Q,Rozelle AL,Lepus CM,et al.Identification of a central role for complement in osteoarthritis[J].Nat Med,2011,17(12):1674-1679.
[13]Bondeson J,Wainwright S,Hughes C,et al.The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis[J].Arthritis Rheum,2010,62(3):647-657.
[14]de Lange-Brokaar BJ,Ioan-Facsinay A,van Osch GJ,et al.Synovial inflammation,immune cells and their cytokines in osteoarthritis:a review[J].Osteoarthritis Cartilage,2012,20(12):1484-1499.
[15]Nakano S,Mishiro T,Takahara S,et al.Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis[J].Clin Rheumatol,2007,26(8):1284-1292.
[16]Bridges AJ,Malone DG,Judy Jicinsky BS,et al.Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis.Relationship to disease type,clinical activity,and antirheumatic therapy[J].Arthritis Rheum,1991,34(9):1116-1124.
[17]Richter M,Trzeciak T,Owecki M,et al.The role of adipocytokines in the pathogenesis of knee joint osteoarthritis[J].Int Orthop.2015,39(6):1211-1217.
[18]Presle N,Pottie P,Dumond H,et al.Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis.Contribution of joint tissues to their articular production[J].Osteoarthritis Cartilage,2006,14(7):690-695.
[19]Luo Y,Liu M.Adiponectin:a versatile player of innate immunity[J].J Mol Cell Biol,2016,8(2):120-128.
[20]Murata M,Otsuka M,Ashida N,et al.Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats[J].Exp Lung Res,2016,42(6):314-321.
[21]Reinhardt A,Wehle M,Geissner A,et al.Structure binding relationship of human surfactant protein D and various lipopolysaccharide inner core structures[J].J Struct Biol,2016,195(3):387-395.
[22]Sorensen GL,Husby S,Holmskov U.Surfactant protein A and surfactant protein D variation in pulmonary disease[J].Immunobiology,2007,212(45):381-416.
[23]Zhou Y,Ming JH,Li YM,et al.Surfactant protein D attenuates nitric oxide-stimulated apoptosis in rat chondrocyte by suppressing p38 MAPK signaling[J].Biochem Biophys Res Commun,2018,495(1):526-532.
[24]Hillaire ML,Haagsman HP,Osterhaus AD,et al.Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections[J].J Innate Immun,2013,5(3):197-208.
[25]Christensen AF,Sorensen GL,Junker K,et al.Localization of surfactant protein-D in the rheumatoid synovial membrane[J].APMIS,2018,126(1):9-13.
[26]Kristiansen M,Frisch M,Madsen HO,et al.Smoking and polymorphisms of genes encoding mannose-binding lectin and surfactant protein-D in patients with rheumatoid arthritis[J].Rheumatol Int,2014,34(3):373-380.
[27]Vandivier RW,Ogden CA,Fadok VA,et al.Role of surfactant proteins A,D,and C1q in the clearance of apoptotic cells in vivo and in vitro:calreticulin and CD91 as a common collectin receptor complex[J].J Immunol,2002,169(7):3978-3986.
[28]Liu Z,Shi Q,Liu J,et al.Innate immune molecule surfactant protein D attenuates sepsis-induced acute pancreatic injury through modulating apoptosis and NF-κB-mediated inflammation[J].Sci Rep,2015,5(4):149-170.
[29]Liu J,AbdelRazek O,Liu Z,et al.Role of surfactant proteins A and D in sepsis-induced acute kidney injury[J].Shock,2014,43(1):31-38.
[30]Du X,Meng Q,Sharif A,et al.Surfactant proteins SP-A and SP-D ameliorate pneumonia severity and intestinal injury in a murine model of staphylococcus aureus pneumonia[J].Shock,2016,46(2):164-172.
[31]Sarashina-Kida H,Negishi H,Nishio J,et al.Gallbladder-derived surfactant protein D regulates gut commensal bacteria for maintaining intestinal homeostasis[J].Proc Natl Acad Sci USA,2017,114(38):10178-10183.
[32]Rokade S,Kishore U,Madan T.Surfactant protein D regulates murine testicular immune milieu and sperm functions[J].Am J Reprod Immunol,2017,77(3):doi:10.1111/aji.12629.
[33]Kumral A,Iscan B,Engur D,et al.Intranasal surfactant protein D as neuroprotective rescue in a neonatal rat model of periventricular leukomalacia[J].J Matern Fetal Neonatal Med,2017,30 (4):446-451.
[34]Mahajan L,Gautam P,Dodagatta-Marri E,et al.Surfactant protein SP-D modulates activity of immune cells:proteomic profiling of its interaction with eosinophilic cells[J].Expert Rev Proteomics,2014,11(3):355-369.
[35]Rahmati M,Mobasheri A,Mozafari M.Inflammatory mediators in osteoarthritis:A critical review of the state-of-the-art,current prospects,and future challenges[J].Bone,2016,85(4):81-90.
[36]Foster MW,Hess DT,Stamler JS.Protein S-nitrosylation in health and disease:a current perspective[J].Trends Mol Med,2009,15(9):391-404.
[37]Yamazoe M,Nishitani C,Takahashi M,et al.Pulmonary surfactant protein D inhibits lipopolysaccharide (LPS)-induced inflammatory cell responses by altering LPS binding to its receptors[J].J Biol Chem,2008,283(51):35878-35888.
[38]Atochina-Vasserman EN.S-nitrosylation of surfactant protein D as a modulator of pulmonary inflammation[J].Biochim Biophys Acta,2012,1820(6):763-769.
[39]Ahn KS,Sethi G,Aggarwal BB.Nuclear factor-kappa B:from clone to clinic[J].Curr Mol Med,2007,7(7):619-637.
[40]Zhang HB,Zhang Y,Chen C,et al.Pioglitazone inhibits advanced glycation end product-induced matrix metalloproteinases and apoptosis by suppressing the activation of MAPK and NF-κB[J].Apoptosis,2016,21(10):1082-1093.